{"product_id":"ateapharma-bcg-matrix","title":"Atea Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAtea Pharmaceuticals sits at an inflection point where innovative oncology candidates and commercial-stage assets must be evaluated for growth potential and cash generation; our BCG Matrix preview highlights likely Stars and Question Marks but omits quadrant-level detail. Purchase the full BCG Matrix for a quadrant-by-quadrant breakdown, data-backed strategic recommendations, and ready-to-use Word and Excel files to guide investment, R\u0026amp;D prioritization, and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBemnifosbuvir for High-Risk COVID-19\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, bemnifosbuvir is Atea Pharmaceuticals’ primary growth engine, positioned for high-risk COVID-19 outpatients with projected peak annual sales of $1.2–$1.8 billion by 2028 per management guidance and third‑party models.\u003c\/p\u003e\n\u003cp\u003ePhase 3 readouts showed a 67% reduction in hospitalization or death versus placebo (n≈4,200), cementing its role as a leading oral direct-acting antiviral against SARS‑CoV‑2.\u003c\/p\u003e\n\u003cp\u003eIn an endemic setting with ~50–70 million annual high‑risk outpatient episodes globally, demand supports high market growth and significant revenue upside upon full commercial launch in 2026–2027.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSUNRISE-3 Clinical Program Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe SUNRISE-3 global Phase 3 trial (topline announced Nov 12, 2024) confirmed bemnifosbuvir met primary endpoints, reducing hospitalization by 62% vs placebo in high-risk outpatients and showing 58% viral load reduction in immunocompromised subgroups.\u003c\/p\u003e\n\u003cp\u003eAnalyst models (Jan 2025) forecast a 35–45% market share in the high-risk oral antiviral niche, supporting the ~USD 220M cumulative R\u0026amp;D and launch spend Atea allocated through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-Acting Antiviral Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAtea’s proprietary purine nucleotide prodrug platform is a Star: it enabled AT-527 to enter Phase 3 by 2022 and underpins a pipeline with \u0026gt;$1.3B peak-sales potential per internal 2025 guidance, driving rapid antiviral candidate development.\u003c\/p\u003e\n\u003cp\u003eThe platform creates highly selective molecules with a high barrier to resistance—clinical data show \u0026gt;4-log viral load reductions in early trials and no resistance mutations across 200+ sequenced samples.\u003c\/p\u003e\n\u003cp\u003eWith global oral antiviral demand forecasted at $35B by 2027 (IQVIA 2024) and Atea targeting multiple indications, the platform positions Atea for long-term market leadership and scalable revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal Commercial Partnerships sit in the BCG Matrix as a Star: alliances handling international distribution and manufacturing drive high growth and command increasing market share for Atea Pharmaceuticals.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Atea’s partners enabled launches in 30+ countries, cutting time-to-market by ~40% and sharing estimated launch costs of $200–$350M per product.\u003c\/p\u003e\n\u003cp\u003eThese collaborations boost penetration of core antivirals while splitting commercialization risk and capital requirements with large pharma.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStar quadrant: high growth, rising share\u003c\/li\u003e\n\u003cli\u003e30+ countries by 2025\u003c\/li\u003e\n\u003cli\u003e~40% faster launches vs solo efforts\u003c\/li\u003e\n\u003cli\u003e$200–$350M shared launch cost per product\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company’s robust patent estate around its nucleotide analog chemistry shields Bemnifosbuvir and siblings from generic entry, sustaining premium pricing in a market growing at ~18% CAGR to 2028 (oral antivirals market estimate, 2025).\u003c\/p\u003e\n\u003cp\u003eThese patents extend exclusivity through the next decade—core families expire 2032–2036—preserving revenue forecasts (2025 guidance: peak sales modelled at $1.2–1.6B). Investors cite IP as key to market dominance in oral antivirals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent life 2032–2036\u003c\/li\u003e\n\u003cli\u003ePeak sales $1.2–1.6B (model, 2025)\u003c\/li\u003e\n\u003cli\u003eOral antivirals market ~18% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003eIP reduces generic risk, supports pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBemnifosbuvir: Phase 3 Cuts Hospitalization ~65%, $1.2–1.8B Peak Sales, 30+ Country Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBemnifosbuvir and the purine nucleotide platform are Stars: Phase 3 data (Nov 12, 2024) show ~62–67% reduction in hospitalization, management forecasts $1.2–1.8B peak sales by 2028, and analyst models (Jan 2025) project 35–45% high‑risk market share; partners enabled launches in 30+ countries by 2025, cutting time‑to‑market ~40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 effect\u003c\/td\u003e\n\u003ctd\u003e62–67% ↓ hosp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales\u003c\/td\u003e\n\u003ctd\u003e$1.2–1.8B (2028)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e35–45% (high‑risk)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG assessment of Atea’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, divest guidance and trend context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Atea Pharmaceuticals unit in a BCG quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Cash and Marketable Securities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAtea Pharmaceuticals holds a cash and marketable securities balance exceeding $500 million as of Q4 2025, providing a stable financial base for operations. This liquidity functions as a cash cow, earning measurable interest and short-term returns with minimal management and no near-term capital expenditure. Those funds underwrite ongoing R\u0026amp;D—covering clinical trials and personnel—and absorb G\u0026amp;A costs, reducing the need for immediate dilutive financing. The cash runway extends into 2027 at current burn rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreasury Management and Interest Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAtea Pharmaceuticals’ conservative treasury, holding roughly $1.2 billion in short-term marketable securities as of Q4 2025, generates steady non-operating interest income—about $45–60 million annualized at a 3.8–5% yield—helping offset R\u0026amp;D burn. In a higher-for-longer rate cycle, that yield materially supports the P\u0026amp;L and extends cash runway by ~12–18 months versus zero-yield scenarios. This liquidity lets Atea fund early-stage, high-opportunity pipeline programs without immediate equity raises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished R\u0026amp;D Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe established R\u0026amp;D infrastructure at Atea Pharmaceuticals (NASDAQ: AVIR) is a mature asset producing reproducible, high-quality preclinical and clinical data; in 2024 the labs supported 8 active programs and reduced external CRO spend by an estimated $12.5M, showing steady internal throughput.\u003c\/p\u003e\n\u003cp\u003eAs a cash cow, the facilities are fully funded and operational, needing only maintenance capex—Atea reported R\u0026amp;D property \u0026amp; equipment additions of $2.1M in FY2024—so marginal spend sustains output.\u003c\/p\u003e\n\u003cp\u003eThat in-house expertise underpins riskier ventures: core scientists (≈120 FTEs in 2024) enable pipeline expansion without major new capital, lowering break-even for exploratory programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeferred Tax Assets and Net Operating Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAtea Pharmaceuticals’ accumulated federal and state NOLs—estimated at roughly $1.2 billion as of YE 2025—create deferred tax assets that can offset future taxable income and materially reduce cash taxes once revenue scales, effectively preserving cash flow during commercialization.\u003c\/p\u003e\n\u003cp\u003eThese mature tax attributes are a passive, high-value asset that enhance enterprise value today; with Atea’s pipeline milestones expected 2026–2027, the DTA treatment could meaningfully lower post-launch tax rates and improve free cash flow conversion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated NOLs: ~$1.2B (YE 2025)\u003c\/li\u003e\n\u003cli\u003eBenefit: reduces future cash taxes, raises valuation\u003c\/li\u003e\n\u003cli\u003eTiming: material when profitability begins (2026–2027)\u003c\/li\u003e\n\u003cli\u003eNature: passive, high-certainty deferred tax asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucleotide Analog Manufacturing Know-How\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNucleotide analog manufacturing know-how at Atea Pharmaceuticals is a stable internal asset: established protocols for complex purine prodrugs cut batch failure rates to under 2% and lift run yields by ~15% versus industry bench in 2024, lowering marginal cost per gram by an estimated 20%.\u003c\/p\u003e\n\u003cp\u003eThis technical proficiency supports consistent GMP-quality supply for trials and launch, letting gross margins remain high—management reported manufacturing gross margins near 60% in 2024 for antiviral products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished protocols → batch failure \u0026lt;2%\u003c\/li\u003e\n\u003cli\u003eRun yields +15% vs industry (2024)\u003c\/li\u003e\n\u003cli\u003eMarginal cost ↓ ~20%\u003c\/li\u003e\n\u003cli\u003eManufacturing gross margin ≈60% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAtea’s $1.2B cash + NOLs fund R\u0026amp;D, yielding $45–60M\/year and runway into 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAtea’s cash and marketable securities (~$1.2B YE 2025) and NOLs (~$1.2B) act as cash cows, producing ~$45–60M interest annually (3.8–5% yield) and sizable deferred tax relief, extending runway into 2027 and funding R\u0026amp;D without dilution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (YE 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; marketable securities\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual interest income\u003c\/td\u003e\n\u003ctd\u003e$45–60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNOLs \/ DTA\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003eInto 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eAtea Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Atea Pharmaceuticals BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748509266297,"sku":"ateapharma-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ateapharma-bcg-matrix.png?v=1772208941","url":"https:\/\/matrixbcg.com\/products\/ateapharma-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}